AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

For more recent analysis of Hayat Tahrir al Sham (HTS), see this August 2023 post from the Warfare, Irregular Threats, and Terrorism Program's Examining Extremism series. Hay’at Tahrir al-Sham (HTS or ...

‘That is clear. ‘He has talent. He needs to learn to play in a different position. He needs to play better inside. He improves a lot recovering (his) position when he doesn’t have the ball.

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several ... And now the immunology duo has paved the way for a “clear runway to growth over the next eight years,” CEO ...

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO ...

NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

Jan 13 (Reuters) - AbbVie (ABBV.N), opens new tab has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's (2096.HK), opens new tab unit for markets ...

NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 ...